GLOW Blend (BPC-157 + TB-500 + GHK-Cu)
Multi-component research blend
A research-supplier blend combining BPC-157, TB-500, and GHK-Cu, three peptides referenced in dermal and tissue-repair research contexts.
Overview
GLOW is a marketed research blend combining BPC-157, TB-500, and GHK-Cu. It is not a naturally occurring substance and exists only as a formulated combination whose exact composition may vary by supplier.
At a glance
What GLOW Blend (BPC-157 + TB-500 + GHK-Cu) does
GLOW is a combination ('blend') peptide product that stacks three mechanistically distinct regenerative peptides — GHK-Cu (the copper tripeptide), BPC-157 (a stable gastric-derived peptide fragment), and TB-500 (a synthetic fragment of thymosin β-4). It is marketed toward skin rejuvenation and tissue repair, the idea being that the three components act on complementary repair pathways so the combination covers more of the healing process than any single peptide. The 'glow' name references the skin/aesthetic angle, though the same blend is promoted for general recovery.
The rationale for the combination follows from what each component does. GHK-Cu supplies matrix-remodeling and pro-angiogenic signaling — stimulating collagen and elastin synthesis, rebalancing MMPs, and promoting new blood-vessel formation. TB-500 (thymosin β-4 fragment) binds actin and is studied for promoting cell migration, epithelial/endothelial repair and reduced fibrotic scarring. BPC-157 is studied preclinically for angiogenesis, tendon/ligament and gut healing and for cytoprotection. Together the pitch is that GHK-Cu drives matrix rebuilding and vascularization while BPC-157 and TB-500 support cell migration, epithelial repair and anti-fibrotic remodeling — covering angiogenesis, matrix synthesis and wound remodeling simultaneously.
The critical caveat is the evidence: while each individual peptide has its own preclinical (and, for GHK-Cu, some human) research, the GLOW blend as a specific fixed combination has essentially no controlled clinical trials demonstrating that the stack outperforms its parts. Claimed synergy is a mechanistic argument, not a proven outcome. The product is sold as a research peptide, and BPC-157 and TB-500 are injectable rather than established topical cosmetic ingredients.
Effects reported in research
- Combines three complementary repair peptides — GHK-Cu (matrix remodeling), TB-500 (actin-binding, cell migration), BPC-157 (angiogenesis/cytoprotection).
- GHK-Cu component stimulates collagen and elastin synthesis and rebalances MMP/TIMP matrix remodeling (in-vitro/preclinical).
- GHK-Cu and BPC-157 components promote angiogenesis / new blood-vessel formation in wound models (preclinical).
- TB-500 (thymosin β-4 fragment) component binds actin and is studied for cell migration and epithelial repair (preclinical).
- BPC-157 component is studied preclinically for tendon/ligament and gastrointestinal healing and tissue protection.
- TB-500 and BPC-157 components are studied for reduced fibrotic scarring during remodeling (preclinical).
- Claimed 'synergy' across angiogenesis, matrix synthesis and remodeling is a mechanistic rationale, not a clinically proven outcome for the fixed blend.
- No controlled clinical trials exist for the GLOW combination itself; sold as a research peptide, with BPC-157/TB-500 typically injectable rather than topical.
Effects listed reflect findings reported in the research literature — many in animal or in-vitro models. Listing an effect is not a claim of efficacy or a therapeutic indication in humans.
Mechanism of action
As a blend, GLOW combines the documented properties of its components: BPC-157's angiogenesis and growth-factor-related repair signaling, TB-500's actin regulation and cell-migration activity, and GHK-Cu's copper-delivery and extracellular-matrix remodeling signaling. These properties derive from separate preclinical and cosmetic research; the combined formulation itself is not validated in controlled human trials.
Mechanistic description reflects published research-literature understanding. Much peptide research is preclinical (in-vitro or animal-model); mechanism in humans may differ and is not established for many compounds.
What it's studied for
Research contexts in which GLOW Blend (BPC-157 + TB-500 + GHK-Cu) appears in the literature. Listing a research area is not a claim of efficacy or a therapeutic indication.
Key characteristics
- A three-component blend of BPC-157, TB-500, and GHK-Cu
- Combines the documented properties of its individual components
- Pairs repair-focused peptides with a copper skin-remodeling tripeptide
- The blend as a whole lacks dedicated clinical validation
- GHK-Cu is a cosmetic ingredient while BPC-157 and TB-500 are research-only
Reported research dosing reference only
Educational reference, not dosing guidance. The figures below summarize amounts reported in published research and research-community protocols, provided for educational and research context only. They are not medical advice, not a recommendation, and not instructions for human use. GLOW Blend (BPC-157 + TB-500 + GHK-Cu) is a research compound.
The GLOW blend combines three peptides, so reported research figures describe each component; the blend ratio determines how much of each is delivered per unit. These are reference figures for research context only, not human dosing guidance.
- BPC-157 component: research reference ~250-500 mcg subcutaneously, often split twice daily
- TB-500 component: research reference ~2-3 mg, often once daily or every other day
- GHK-Cu component: research reference ~1-2 mg, often split dosing
- Common pre-blend ratio: 5:1:1 GHK-Cu:TB-500:BPC-157
Differing half-lives across the three components mean a blended schedule is a compromise; check the COA for the exact per-component amounts.
How it compares
GLOW is oriented toward combined skin and tissue-repair research, adding the copper tripeptide GHK-Cu to the BPC-157/TB-500 pairing found in simpler blends.
Blend components
This entry documents a research-supplier blend combining the following. Each component is documented as its own PeptiDex entry where available:
Commonly studied alongside
Compounds frequently researched together with GLOW Blend (BPC-157 + TB-500 + GHK-Cu) in the literature. Cross-referenced for research context — not a usage or combination recommendation.
Handling & Stability
Lyophilized peptides are stored cold, protected from light, and reconstituted only at the time of intended in-vitro work.
- Avoid repeated freeze-thaw cycles
- Verify supplier lot and Certificate of Analysis
- Follow institutional lab-safety protocols
Analytical & COA Concepts
Reputable research suppliers publish a third-party Certificate of Analysis per batch. Key analytical concepts referenced in COAs include:
Category Context
GLOW Blend (BPC-157 + TB-500 + GHK-Cu) sits in the Cosmetic & Dermal area of the PeptiDex library.
- Entry type: Research-supplier blend
- Browse the full library →
- Glossary of terms →
Where researchers source GLOW Blend (BPC-157 + TB-500 + GHK-Cu)
For researchers studying GLOW Blend (BPC-157 + TB-500 + GHK-Cu), third-party suppliers such as Practically Natty Peptides offer research-grade material with third-party Certificates of Analysis and US-based shipping.
View research-supplier listing →
Outbound link to a third-party research supplier. Inclusion does not constitute endorsement; all editorial content is developed independently.
Frequently asked questions
What is the GLOW blend?
The GLOW blend is a research-peptide combination of BPC-157, TB-500, and GHK-Cu. Each component targets a different aspect of tissue and skin remodeling, and the blend is studied together rather than as a single approved drug.
What does each component contribute?
In research framing, BPC-157 is associated with angiogenesis (new blood-vessel growth) at injury sites, TB-500 with actin regulation and migration of repair cells, and GHK-Cu with copper delivery and collagen/elastin matrix remodeling. The rationale is complementary, non-overlapping mechanisms.
What ratio is the GLOW blend usually sold in?
Many GLOW research products are pre-blended in a 5:1:1 ratio of GHK-Cu to TB-500 to BPC-157 (for example 50 mg GHK-Cu, 10 mg TB-500, 10 mg BPC-157 per vial). Ratios vary by supplier, so the certificate of analysis should be checked for the exact amounts.
How does GLOW differ from KLOW?
GLOW is BPC-157 + TB-500 + GHK-Cu. KLOW adds a fourth component, KPV (an anti-inflammatory alpha-MSH fragment), to the same three, so KLOW is essentially GLOW plus KPV. Both are studied in tissue-repair and skin-quality contexts.
Why do the components have different dosing rhythms?
Their pharmacokinetics differ: BPC-157's shorter half-life (cited around 4-6 hours) is associated with split/twice-daily research dosing, while TB-500's longer plasma stability supports less frequent dosing, and GHK-Cu has rapid tissue uptake but short circulation. Blends therefore represent a compromise dosing schedule.
Is the GLOW blend an approved therapy?
No. BPC-157, TB-500, and GHK-Cu are not FDA-approved for human therapy; the blend is sold for research use only and is not a treatment for any condition.
Answers are educational summaries of research-literature context and do not constitute medical advice. See the Research Library, COA guide, and Storage & Handling guide for more.